Jacqui Hoffman

Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

Ted W. Johnson, Paul Richardson, Simon Bailey et al. · Journal of Medicinal Chemistry · 2014 · 585 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib

Qinhua Huang, Ted W. Johnson, Simon Bailey et al. · Journal of Medicinal Chemistry · 2014 · 118 citations · Full text

Medicine, Oncology, Pharmacology +14

Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1 <i>H</i> -[1,2,3]triazolo[4,5- <i>b</i> ]pyrazin-6-yl)-1 <i>H</i> -pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer

J. Jean Cui, Michele McTigue, Mitchell D. Nambu et al. · Journal of Medicinal Chemistry · 2012 · 105 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design

Hengmiao Cheng, Chunze Li, Simon Bailey et al. · ACS Medicinal Chemistry Letters · 2012 · 81 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design

Hengmiao Cheng, Shubha Bagrodia, Simon Bailey et al. · MedChemComm · 2010 · 73 citations · Full text

Pharmacy, Oncology, Pharmacology +17